U.S. Markets closed

Uterine Fibroids Clinical Trial Pipeline Highlights 2019 - Global Forecast to 2024 by Clinical Trial Stage, Drug Mechanism Class, Company - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--

The "Global Uterine Fibroids Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Uterine Fibroids Pipeline Highlights - 2019, provides most up-to-date information on key pipeline products in the global Uterine Fibroids market.

It covers emerging therapies for Uterine Fibroids in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Uterine Fibroids pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Uterine Fibroids pipeline products by their dominant mechanism of action/drug class. This helps executives categorize products based on their drug class and also assess the strengths and weaknesses of compounds.

Company:

The report provides Uterine Fibroids pipeline products by the company.

Short-term Launch Highlights:

Find out which Uterine Fibroids pipeline products will be launched in the US and Ex-US till 2024.

Key Topics Covered:

1. Uterine Fibroids Pipeline by Stages

2. Uterine Fibroids Phase 3 Clinical Trial Insights

3. Uterine Fibroids Phase 2 Clinical Trial Insights

4. Uterine Fibroids Phase 1 Clinical Trial Insights

5. Uterine Fibroids Preclinical Research Insights

6. Uterine Fibroids Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/u3yilz

View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005697/en/